Myriad Genetics Inc. furthered its companion diagnostics cancer play with a new collaboration with drug firms and the expansion of an existing partnership.
Myriad announced Feb. 22 that it has inked a deal with Tesaro Inc. and Merck & Co. Inc. to use Myriad's myChoice HRD (homologous recombination deficient) diagnostic offering...